PubRank

Wataru Sugiura

Author PubWeight™ 58.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005 3.17
2 Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 2007 2.49
3 The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat Struct Mol Biol 2012 1.36
4 Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004 1.31
5 Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003 1.30
6 Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. J Virol 2005 1.19
7 Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease. J Mol Biol 2007 1.14
8 Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 2010 1.08
9 Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006 1.08
10 HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc Natl Acad Sci U S A 2009 1.06
11 Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. AIDS Res Hum Retroviruses 2007 1.02
12 The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. J Virol 2010 0.99
13 Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis 2007 0.98
14 Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res 2006 0.97
15 Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations. J Med Chem 2007 0.96
16 Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002 0.94
17 The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions. Retrovirology 2014 0.92
18 Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M. J Am Chem Soc 2006 0.92
19 Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 2011 0.92
20 HIV-2 CRF01_AB: first circulating recombinant form of HIV-2. J Acquir Immune Defic Syndr 2010 0.91
21 HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana. PLoS One 2013 0.91
22 Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs. J Clin Microbiol 2006 0.90
23 Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J Phys Chem B 2005 0.87
24 Molecular dynamics simulation in virus research. Front Microbiol 2012 0.87
25 Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiol 2011 0.86
26 Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6. J Virol 2008 0.86
27 Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. PLoS One 2013 0.85
28 Change of positive selection pressure on HIV-1 envelope gene inferred by early and recent samples. PLoS One 2011 0.85
29 A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity. Antivir Chem Chemother 2005 0.85
30 High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma. Biol Pharm Bull 2010 0.85
31 Molecular epidemiology of HIV type 1 infection in Iran: genomic evidence of CRF35_AD predominance and CRF01_AE infection among individuals associated with injection drug use. AIDS Res Hum Retroviruses 2012 0.84
32 Peptide HIV-1 integrase inhibitors from HIV-1 gene products. J Med Chem 2010 0.83
33 TRIM5 genotypes in cynomolgus monkeys primarily influence inter-individual diversity in susceptibility to monkey-tropic human immunodeficiency virus type 1. J Gen Virol 2013 0.83
34 The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. PLoS One 2012 0.82
35 APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese. Immunogenetics 2015 0.82
36 Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther 2004 0.82
37 A simple competitive RT-PCR assay for quantitation of HIV-1 subtype B and non-B RNA in plasma. J Virol Methods 2007 0.82
38 Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin. Antivir Chem Chemother 2006 0.81
39 Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort. Antiviral Res 2010 0.81
40 Analysis of HIV-1 sequences before and after co-infecting syphilis. Microbes Infect 2006 0.81
41 Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case. Antiviral Res 2011 0.81
42 Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations. J Med Invest 2013 0.80
43 Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses. J Infect Dis 2008 0.80
44 Fungal phenalenones inhibit HIV-1 integrase. J Antibiot (Tokyo) 2005 0.80
45 Detecting immunoglobulin M antibodies against microsporidian Encephalitozoon cuniculi polar tubes in sera from healthy and human immunodeficiency virus-infected persons in Japan. Clin Vaccine Immunol 2006 0.79
46 Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J Virol Methods 2002 0.79
47 Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency. AIDS Res Ther 2012 0.79
48 Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. BMC Bioinformatics 2009 0.79
49 Short communication: lack of correlation between UGT1A1*6, *28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients. AIDS Res Hum Retroviruses 2011 0.78
50 Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan. J Acquir Immune Defic Syndr 2016 0.78
51 Differentiation of subtypes B and E of human immunodeficiency virus type 1 by polymerase chain reaction using novel env gene primers. J Virol Methods 2002 0.78
52 Molecular and enzymatic characterization of XMRV protease by a cell-free proteolytic analysis. J Proteomics 2012 0.78
53 Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity. Clin Infect Dis 2013 0.78
54 Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med 2015 0.78
55 Mutations to the probe of Cobas TaqMan HIV-1 ver. 1.0 assay causing undetectable viral load in a patient with acute HIV-1 infection. J Infect Chemother 2011 0.78
56 Structural and energetic analysis on the complexes of clinically isolated subtype C HIV-1 proteases and approved inhibitors by molecular dynamics simulation. J Phys Chem B 2010 0.77
57 Seroprevalence of Kaposi's sarcoma-associated herpesvirus among men who have sex with men in Japan. J Med Virol 2013 0.77
58 Phenotype and function of GM-CSF independent dendritic cells generated by long-term propagation of rat bone marrow cells. Cell Immunol 2004 0.77
59 Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material. AIDS Res Hum Retroviruses 2014 0.77
60 The Prevalence of High Antiretroviral Coverage and Viral Suppression in Japan: an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum. Jpn J Infect Dis 2016 0.76
61 Immunological behavior of enhanced green fluorescent protein (EGFP) as a minor histocompatibility antigen with a special reference to skin isograft and specific regulation of local graft-versus-host reaction (GvHR). Immunol Lett 2009 0.76
62 [Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center]. Nihon Shokakibyo Gakkai Zasshi 2012 0.76
63 Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome. Intern Med 2016 0.75
64 [The current status of drug-resistant HIV and its management in Japan]. Nihon Naika Gakkai Zasshi 2009 0.75
65 Sensitization to enhanced green fluorescence protein minor histocompatibility antigen by gene transduction into dendritic cells and peritoneal exudate macrophages. Transpl Immunol 2007 0.75
66 An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin. Intern Med 2015 0.75
67 Study of antiretroviral drug-resistant HIV-1 genotypes in northern Thailand: role of mutagenically separated polymerase chain reaction as a tool for monitoring zidovudine-resistant HIV-1 in resource-limited settings. J Acquir Immune Defic Syndr 2004 0.75
68 Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure. Jpn J Infect Dis 2002 0.75
69 An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V. AIDS Res Hum Retroviruses 2007 0.75
70 [Current topics on drug-resistant HIV in Japan]. Nihon Rinsho 2010 0.75
71 Polymorphisms and haplotypes of the CD209L gene and their association with the clinical courses of HIV-positive Japanese patients. Jpn J Infect Dis 2002 0.75